株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

注目市場の分析:セリアック病

Market Spotlight: Celiac Disease

発行 Datamonitor Healthcare 商品コード 633145
出版日 ページ情報 英文 27 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.55円で換算しております。
Back to Top
注目市場の分析:セリアック病 Market Spotlight: Celiac Disease
出版日: 2019年08月23日 ページ情報: 英文 27 Pages
概要

世界のセリアック病の有病者数は2016年の約8850万人、2025年には9740万人に増加すると予測されています。

当レポートでは、世界のセリアック病の治療薬の市場を調査し、疾患の背景・概要、有病者数の10ヵ年予測、主な治療法、主なパイプライン薬の概要、ライセンシング・資産買収など企業間の主な取引の動向、特許情報、臨床試験の状況などをまとめています。

概要

主な要点

疾患の背景

  • サブタイプ

治療

疫学

パイプライン薬

今後の主なイベント

ライセンシング・資産買収契約

  • 武田薬品工業による資金供給・買収準備の可能性も

親特許

臨床試験環境

文献

付録

目次
Product Code: DMKC0181038

This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were approximately 89.9 million prevalent cases of celiac disease worldwide, and forecasts that number to increase to 98.8 million prevalent cases by

2026. Prevalence of celiac disease is highest in Europe and Northern America, and lowest in Africa and Oceania.

All industry-sponsored drugs in active clinical development for celiac disease are in Phase I or Phase II. Therapies in development for celiac disease focus on targets such as gluten, interleukin-15, interleukin-15 receptor, zonulin and zonulin receptor, immune system, and T-cell receptor. Pipeline drugs for celiac disease are administered orally, as well as via the subcutaneous, intradermal, and intravenous routes.

The release of topline Phase III trial results for INN-202 is the only high-impact upcoming event in the celiac disease space. The overall likelihood of approval of a Phase I autoimmune/immunology asset is 14.7%, and the average probability a drug advances from Phase III is 68.9%. Drugs, on average, take 8.8 years from Phase I to approval in the overall autoimmune/immunology space.

There have been five licensing and asset acquisition deals involving celiac disease drugs during 2014-19. The largest deal during the period was the $170m licensing and co-development agreement signed in 2018 between Amgen and Provention Bio for the development of anti-IL-15 antibody AMG 714 for the treatment of gluten-free diet non-responsive celiac disease.

The distribution of clinical trials across Phase I-III indicates that the vast majority of trials for celiac disease have been in the mid and late phases of development, with 91% of trials in Phase II-III, and only 9% in Phase I.

The US has a substantial lead in the number of celiac disease clinical trials globally. Innovate Biopharmaceuticals has the highest number of completed trials for celiac disease, with six trials, and also leads industry sponsors with the highest number of clinical trials for celiac disease overall.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

EPIDEMIOLOGY

PIPELINE DRUGS

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Parvus, Genentech Collaborate On IBD, Celiac And Liver Disease
  • Amgen Links With Provention For AMG 714 In Celiac Disease

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of celiac disease, 2017-26
  • Figure 2: Overview of pipeline drugs for celiac disease in the US
  • Figure 3: Pipeline drugs for celiac disease, by company
  • Figure 4: Pipeline drugs for celiac disease, by drug type
  • Figure 5: Pipeline drugs for celiac disease, by classification
  • Figure 6: Key upcoming events in celiac disease
  • Figure 7: Probability of success in the celiac disease pipeline
  • Figure 8: Licensing and asset acquisition deals in celiac disease, 2014-19
  • Figure 9: Clinical trials in celiac disease
  • Figure 10: Top 10 drugs for clinical trials in celiac disease
  • Figure 11: Top 10 companies for clinical trials in celiac disease
  • Figure 12: Trial locations in celiac disease
  • Figure 13: Celiac disease trials status
  • Figure 14: Celiac disease trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of celiac disease, 2017-26
  • Table 2: Prevalence proportions of celiac disease, by age group, 2017
  • Table 3: Pipeline drugs for celiac disease in the US
Back to Top